Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis.
about
Planned neck dissection following chemo-radiotherapy in advanced HNSCCEvaluating the role of quality assessment of primary studies in systematic reviews of cancer practice guidelinesPreservation of organ function in head and neck cancer.Evaluation of the larynx for tumour recurrence by diffusion-weighted MRI after radiotherapy: initial experience in four cases.Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma.Clinical outcomes of nedaplatin and S-1 treatment with concurrent radiotherapy in advanced head and neck cancer.Treatment Outcomes of Rare Retromolar Trigone Squamous Cell Carcinoma Using Combined Modalities.Squamous cell carcinomas of the head and neck.Concurrent chemoradiotherapy with S-1 in patients with stage III-IV oral squamous cell carcinoma: A retrospective analysis of nodal classification based on the neck node level.Treatment of locally advanced head and neck cancer: historical and critical review.A single centre experience with sequential and concomitant chemoradiotherapy in locally advanced stage IV tonsillar cancerComparison of swallowing function after intensity-modulated radiation therapy and conventional radiotherapy for head and neck cancer.Salvage for cervical recurrences of head and neck cancer with dissection and interstitial high dose rate brachytherapy.A unique complication associated with concurrent chemoradiation for the treatment of locally advanced head and neck cancerAdherence to and uptake of clinical practice guidelines: lessons learned from a clinical practice guideline on chemotherapy concomitant with radiotherapy in head-and-neck cancerEffective health care: management of head and neck cancers(Chemo)radiotherapy after laser microsurgery and selective neck dissection for pN2 head and neck cancer.Bevacizumab plus cisplatin and helical tomotherapy in treatment of locally advanced nasopharyngeal carcinomaGarcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers.Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706).A long-term follow-up study after split-course irradiation with concurrent chemotherapy (carboplatin) for locally advanced head and neck cancer and a review of the literature.Concurrent radiochemotherapy in locally-regionally advanced oropharyngeal squamous cell carcinoma: analysis of treatment results and prognostic factors.Effects of a concurrent chemoradiotherapy with S-1 for locally advanced oral cancer.A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma.Alteration of radiotherapy fractionation and concurrent chemotherapy: a new frontier in head and neck oncology?Nephrotoxicity as a Dose-Limiting Factor in a High-Dose Cisplatin-Based Chemoradiotherapy Regimen for Head and Neck Carcinomas.Primary surgery versus chemoradiotherapy for advanced oropharyngeal cancers: a longitudinal population studyRehabilitation of dysphagia following head and neck cancerToxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancerRadical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience.Treatment-related toxicities in older adults with head and neck cancer: A population-based analysisHead and neck cancer: an evolving treatment paradigm.Randomized phase III trial of concurrent chemoradiotherapy vs accelerated hyperfractionation radiotherapy in locally advanced head and neck cancer.Cetuximab concurrent with IMRT versus cisplatin concurrent with IMRT in locally advanced nasopharyngeal carcinoma: A retrospective matched case-control study.Concurrent chemoradiotherapy with conventional fractionated radiotherapy and low-dose daily cisplatin plus weekly docetaxel for T2N0 glottic cancer.Concurrent chemoradiotherapy with S-1 as first-line treatment for patients with oropharyngeal cancer.Canine tonsillar squamous cell carcinoma -- a multi-centre retrospective review of 44 clinical cases.The treatment of oral cancer: an overview for dental professionals.Recent multidisciplinary approach with molecular targeted drugs for advanced head and neck cancer.Prognostic significance of p16 in locally advanced squamous cell carcinoma of the head and neck treated with concurrent cisplatin and radiotherapy.
P2860
Q24796568-7138E7E6-9ACE-4602-8895-AA3D10108FB3Q24799623-3CF5408B-CC58-4E3B-BA5E-32FF7D5C6411Q30459136-0CC8E2D3-E770-464A-9B51-B635CA523E76Q31038204-6576F238-2F30-43A2-BEE8-6942EBAE7834Q33399402-D6E76C9A-25E6-4503-9824-A61D928AE8FBQ33419263-2FE545F2-9C29-4236-9E66-DB419966DE21Q33746533-5440E894-BB6F-4E51-808D-86E0260C66F5Q33812371-12E03200-504C-479D-8E07-B53CE7280313Q33857915-598BD653-FD72-4C42-99D4-E5E205CA5B74Q34157174-BAB2C75F-DA22-4F63-BCC2-EB01DD463102Q34498577-555DAE50-DB56-433D-8705-2B7BD501100BQ34647102-FF325BD2-366B-4818-BBCF-57DD826509E3Q35016079-EDD05EE3-DD7F-415E-9087-ECFBA785B3C5Q35180964-CCA27980-5F5C-4ECC-B109-3D84B736644DQ35445170-E9A79442-7915-452F-A8CC-1BF065887907Q35527499-53CCF9D0-F5EE-4E5C-9F8D-E488BB497B3EQ35599653-F10599F8-7845-4F31-B1BA-6F52509050BFQ35694417-DA7A273B-452B-4798-B56E-DE7B1FBA409BQ35741628-637CAE92-9621-4D9E-BD9F-AC66F93840B2Q35754239-94760452-B291-494A-B997-3DC28EC0170AQ36019202-A1D829DD-E628-4F17-A1F3-D4F1D24A26EEQ36116471-9EBEC11D-8ECF-45CF-B0E3-8B5F8480765EQ36126517-5012F0BA-90AF-44AB-B03F-CD126F650042Q36220797-F90C7A19-E8B7-4F22-87CB-9F765CEEC455Q36304013-D0B55383-1F38-409C-AC96-41242DD992A6Q36638185-6B2F1597-B76D-4512-AA1B-B7288B00C431Q36888667-195CBBA6-8597-4908-ADEA-E63FF17D657EQ36994833-0A7D2072-5A95-4E60-91DE-0E7B85EDD1EEQ37204943-A581EEF5-7DA7-4D31-9110-38B0B5046368Q37242570-ECEE65B2-4BCC-42C5-B903-6EB21DA6BB41Q37246284-111B2B7B-7198-483D-8446-D5932BD484DAQ37271937-B9B80A10-220B-4442-9196-0A6C9223DCA4Q37297260-47CB6AF5-41B8-4630-981A-E692C1BF72CAQ37605840-14106D4E-0C76-47B7-8A2E-4734716A7F4CQ37655352-692A0381-9B6C-4B5E-B372-D1E087F1C421Q37824214-D32353A8-CB76-40EF-886D-1AE46F4F8A5FQ37897253-F6D44740-870F-4AAA-9460-5691B55FA8F1Q37925053-6F201A58-8B77-4B75-9602-494666E9FBEBQ38191864-586D3206-CACB-4671-9D64-CD487CAB63D4Q38414687-3D79918F-5772-49DE-8F07-1A4AC9D8C544
P2860
Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Choosing a concomitant chemoth ...... rature with subgroup analysis.
@ast
Choosing a concomitant chemoth ...... rature with subgroup analysis.
@en
Choosing a concomitant chemoth ...... rature with subgroup analysis.
@nl
type
label
Choosing a concomitant chemoth ...... rature with subgroup analysis.
@ast
Choosing a concomitant chemoth ...... rature with subgroup analysis.
@en
Choosing a concomitant chemoth ...... rature with subgroup analysis.
@nl
prefLabel
Choosing a concomitant chemoth ...... rature with subgroup analysis.
@ast
Choosing a concomitant chemoth ...... rature with subgroup analysis.
@en
Choosing a concomitant chemoth ...... rature with subgroup analysis.
@nl
P2093
P2860
P356
P1433
P1476
Choosing a concomitant chemoth ...... rature with subgroup analysis.
@en
P2093
Cancer Care Ontario Practice Guideline Initiative Head and Neck Cancer Disease Site Group
D I Hodson
G P Browman
R J Mackenzie
P2860
P304
P356
10.1002/HED.1081
P577
2001-07-01T00:00:00Z